Search →

Overview

Investing In a Better Future

If you’ve come to this page, we hope you are as excited about Bicycle as we are. Our goal is to be one of the world’s leading solid tumor therapeutics companies. Please give us a call or send us an email if you have questions about our science, clinical programs, strategy or any other aspect of the Bicycle story.
Press
Date
Title
Date
01/11/23
Title
Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium
Date
01/04/23
Title
Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Date
11/10/22
Title
Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting
Date
11/08/22
Title
Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update
Overview →Stock Information →SEC Filings →UK Annual Reports →Governance + Leadership →Presentation + Events →Analyst Coverage →Press Releases →Investor Resources →

Search